# 2026年1月8日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 连续肾脏替代治疗过程中聚丙烯腈膜对卡泊芬净的吸附作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498941)
**期刊：** Intensive care medicine
**PMID：** 41498941
**DOI：** 10.1007/s00134-025-08276-3

### 第一部分 原文与翻译

**英文原标题：** Adsorption of caspofungin by polyacrylonitrile membranes during continuous kidney replacement therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂无提供。

### 第二部分 AI 大师评价

本研究围绕连续肾脏替代治疗（CKRT）中抗真菌药物卡泊芬净在聚丙烯腈（PAN）透析膜上的吸附行为展开，旨在评估该材料对药物清除率和血浆暴露的影响。虽然摘要未公开，但根据标题推测，研究可能采用体外实验或临床监测方式比较不同膜材对药物吸附的差异。该工作对危重症患者抗真菌治疗药代动力学的合理调整具有重要参考价值，其创新点在于关注药物—膜相互作用的具体机制。局限性在于缺乏完整结果披露，尚需进一步实证验证。

---

## 2. 阅读观察性研究时的研究方法与统计学检查

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498939)
**期刊：** Intensive care medicine
**PMID：** 41498939
**DOI：** 10.1007/s00134-025-08255-8

### 第一部分 原文与翻译

**英文原标题：** Checking methodology and statistics when reading an observational study.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该文发表于重症医学领域顶级期刊，标题聚焦于阅读观察性研究时对方法学与统计分析的审查。虽然缺乏摘要，但可推测作者旨在提供系统的评估框架，帮助读者识别潜在偏倚与统计陷阱，从而提升对非随机研究结果的批判性理解。该主题对临床研究设计与证据解读具有重要教育意义，但由于缺乏具体实例或实证数据，其应用价值尚待进一步展开。

---

## 3. 自主呼吸型ARDS患者床旁生理变量个体化PEEP的比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498938)
**期刊：** Intensive care medicine
**PMID：** 41498938
**DOI：** 10.1007/s00134-025-08242-z

### 第一部分 原文与翻译

**英文原标题：** Comparison between bedside physiological variables to personalize PEEP in spontaneously breathing patients with ARDS.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于急性呼吸窘迫综合征（ARDS）自主呼吸患者，通过比较床旁可测生理变量来指导个体化滴定呼气末正压（PEEP）。该研究旨在探索无需深镇静或机械通气条件下的PEEP优化方法，对提升ARDS自主呼吸患者的肺保护策略具有潜在意义。尽管缺少摘要，标题已揭示其在精准呼吸治疗与个体化重症管理领域的创新性，但仍需进一步了解其研究设计与临床验证结果。

---

## 4. 侵入性机械通气过程中呼吸用力监测：一项多国临床实践调查

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498937)
**期刊：** Intensive care medicine
**PMID：** 41498937
**DOI：** 10.1007/s00134-025-08256-7

### 第一部分 原文与翻译

**英文原标题：** Monitoring respiratory effort during invasive mechanical ventilation: a multinational survey of clinical practice.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究旨在了解各国临床团队对侵入性机械通气患者呼吸努力监测的当前实践与认知差异。通过多国调查，研究者可能比较了不同地区在监测手段、评估指标及临床决策应用方面的现状。此类调查为统一呼吸监测标准、提升呼吸支持质量提供了重要参考。尽管未提供摘要，但从标题可见其创新性在于跨国比较，可揭示全球实践差异与改进潜力。

---

## 5. 急诊科停留时间延长与危重症患者护理流程指标的关联研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498610)
**期刊：** Critical care medicine
**PMID：** 41498610
**DOI：** 10.1097/CCM.0000000000007028

### 第一部分 原文与翻译

**英文原标题：** Association of Prolonged Emergency Department Length of Stay With Process of Care Measures for Critically Ill Patients.

> **英文摘要：**
> OBJECTIVES: To explore the association between a prolonged emergency department (ED) length of stay and the deployment of process of care measures (e.g., low tidal volume ventilation) for critically ill patients.
> 
> DESIGN: Retrospective cohort study.
> 
> SETTING: Eight academic ICUs in Toronto.
> 
> PATIENTS: Mechanically ventilated adult patients who were directly admitted to the ICU from the ED from June 2014 to February 2023.
> 
> INTERVENTIONS: None.
> 
> MEASUREMENTS AND MAIN RESULTS: The cohort was divided into a short ED stay group (i.e., < 6 hr) and a prolonged ED stay group (i.e., from 6 to 24 hr). We used propensity score methods and multivariable logistic regression models to estimate the association between a prolonged ED stay and the receipt of process of care measures on day 2 after ICU admission, adjusting for baseline characteristics. Associations were reported as odds ratios (ORs) and 95% CIs. We included 7072 patients, of whom 1462 (21%) had a prolonged ED stay. Both groups had comparable severity of illness at baseline. There was no difference in the deployment of processes of care measures on day 2 after ICU admission between the two groups. The adjusted OR for the prolonged ED stay group compared with a short ED stay group for each measure were as follows: low tidal volume ventilation 0.92 (95% CI, 0.68-1.22), spontaneous breathing trial 1.12 (95% CI, 0.92-1.35), extubation among those eligible 0.78 (95% CI, 0.55-1.12), deep vein thrombosis prophylaxis 1.13 (95% CI, 0.95-1.34), and continuous sedation 0.92 (95% CI, 0.81-1.06).
> 
> CONCLUSIONS: In this multicenter study of critically ill adult patients, a prolonged ED stay was not associated with a significant difference in the deployment of evidence-based process of care measures for critically ill adult patients.

> **中文摘要：**
> 研究目的：探讨急诊科（ED）停留时间延长与危重症患者护理流程措施（如低潮气量通气）的实施之间的关联。
> 
> 研究设计：回顾性队列研究。
> 
> 研究地点：多伦多的八所学术重症监护病房（ICU）。
> 
> 研究对象：2014年6月至2023年2月期间，自ED直接收入ICU且接受机械通气的成年患者。
> 
> 干预措施：无。
> 
> 测量与主要结果：研究队列被分为短期ED停留组（<6小时）与延长ED停留组（6至24小时）。研究采用倾向评分法及多变量逻辑回归模型，评估延长ED停留与ICU入院后第2天接受护理流程措施之间的关联，并对基线特征进行调整。关联结果以比值比（OR）及95%置信区间（CI）表示。共纳入7072例患者，其中1462例（21%）为延长ED停留。两组在基线疾病严重程度上基本相当。ICU入院后第2天，两组在护理流程措施的实施上无显著差异。延长ED停留组相较短期组的调整后OR依次为：低潮气量通气0.92（95% CI, 0.68–1.22）、自主呼吸试验1.12（95% CI, 0.92–1.35）、符合拔管条件者拔管0.78（95% CI, 0.55–1.12）、深静脉血栓预防1.13（95% CI, 0.95–1.34）以及持续镇静0.92（95% CI, 0.81–1.06）。
> 
> 结论：在这项多中心研究中，急诊停留时间延长与危重症成人患者接受基于循证的护理流程措施之间无显著差异。

### 第二部分 AI 大师评价

该研究旨在评估急诊停留时间延长对危重症患者进入ICU后的循证护理措施执行情况的影响。研究设计为多中心回顾性队列分析，采用倾向评分和多变量逻辑回归控制混杂因素。结果显示，延长ED停留并未导致ICU早期护理流程实施的显著差异，提示该过程的质量多由ICU内部流程而非急诊停留时间决定。研究具有较高外部有效性，但受限于回顾性设计与潜在信息偏倚。

---

## 6. 先顾“马”再论CAR-T：嵌合抗原受体T细胞治疗耐受性改善下的持续败血症风险

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498608)
**期刊：** Critical care medicine
**PMID：** 41498608
**DOI：** 10.1097/CCM.0000000000007047

### 第一部分 原文与翻译

**英文原标题：** Putting the Horse Before the CAR T Cells: Persistent Sepsis Risks Despite Improved Tolerance of Chimeric Antigen Receptor T-Cell Therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究标题提示作者关注CAR-T细胞治疗耐受性改善后仍存在的持续败血症风险问题，可能探讨免疫恢复与感染易感之间的关系。尽管缺乏摘要，但题目暗示该论文从临床重症监护或免疫学角度审视CAR-T治疗后的感染并发症。文章的创新点在于强调疗效与安全性的平衡及败血症风险管理，提示未来需加强感染监测与免疫支持措施。不过，由于暂无摘要，具体方法与结果仍需进一步查阅原文确认。

---

## 7. 急性肾损伤与谵妄：重思重症监护病房中的器官互作

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498593)
**期刊：** Critical care medicine
**PMID：** 41498593
**DOI：** 10.1097/CCM.0000000000007050

### 第一部分 原文与翻译

**英文原标题：** Acute Kidney Injury and Delirium: Rethinking Organ Crosstalk in the ICU.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文探讨了急性肾损伤与谵妄之间的潜在病理生理联系，提示两者可能通过炎症反应、代谢紊乱及神经-肾轴的机制相互影响。文章提出应从系统层面重新审视重症监护中器官间的互动，以改善多器官功能障碍的预防和治疗策略。尽管缺乏摘要细节，可推测其创新点在于强调“器官间互作”这一整体性视角，但仍可能需要更多实证研究来验证其临床意义。

---

## 8. 血液系统恶性肿瘤患者在重症监护两周期间预后确定性提升有限：为时间限定试验提供依据的分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41498592)
**期刊：** Critical care medicine
**PMID：** 41498592
**DOI：** 10.1097/CCM.0000000000007006

### 第一部分 原文与翻译

**英文原标题：** Minimal Gain in Prognostic Certainty for Patients With Hematologic Malignancies Over 2 Weeks of Intensive Care: An Analysis to Inform Time-Limited Trials.

> **英文摘要：**
> OBJECTIVE: We aimed to examine how the predicted 1-year survival and its prognostic certainty evolve during the first two weeks of ICU admission.
> 
> DESIGN: Retrospective cohort study.
> 
> SETTING: Two academic medical centers in The Netherlands. External validation in the Medical Information Mart for Intensive Care-IV database from a tertiary medical center in the United States.
> 
> PATIENTS: Patients with active hematologic malignancies admitted to the ICU.
> 
> INTERVENTIONS: None.
> 
> MEASUREMENTS AND MAIN RESULTS: Separate prediction models for 1-year survival were developed using data available at day 1, 7, and 14 after ICU admission for 555, 181, and 94 ICU admissions resulting in an area under the receiver operating characteristics curves of 0.71, 0.67, and 0.66, respectively. At the individual patient level, prognostic certainty quantified by entropy increased meaningfully (entropy decrease > 0.25) in 2% of patients between day 1 and day 7 (in an additional 12% certainty increased because of death) and in 14% of patients between day 7 and day 14 (in an additional 18% because of death). Among patients alive on day 1, 2% of patients with an "uncertain" and 10% with a "poor" initial prognosis had shifted to a more favorable category by day 7. Of the patients alive and still in the ICU on day 7, 31% of patients with an "uncertain" and 16% with a "poor" prognosis had shifted to a more favorable category by day 14. Results in the external validation cohort were comparable.
> 
> CONCLUSIONS: In patients with hematologic malignancies admitted to the ICU, prognostic certainty about long-term survival increased little during in the first 2 weeks of ICU admission, aside from increases in prognostic certainty due to early mortality. Despite the use of rich ICU datasets and different state-of-the-art modeling strategies, overall model performance was modest, suggesting that prognosis in this population is largely driven by disease-related and patient-specific factors beyond the ICU course.

> **中文摘要：**
> 研究目的：我们旨在探讨血液系统恶性肿瘤患者在入住重症监护室（ICU）后的前两周内，其预测的一年生存率及预后确定性的变化情况。
> 
> 研究设计：回顾性队列研究。
> 
> 研究场景：荷兰两所学术医疗中心；并在美国一家三级医疗中心的重症监护信息数据库（MIMIC-IV）中进行外部验证。
> 
> 研究对象：入住ICU的活动性血液系统恶性肿瘤患者。
> 
> 干预措施：无。
> 
> 测量与主要结果：分别利用ICU入院后第1天、第7天和第14天可获得的数据，构建了一年生存率预测模型，共纳入555、181和94次ICU入院，模型的受试者工作特征曲线下面积分别为0.71、0.67和0.66。在个体层面上，以熵为指标量化的预后确定性在1日至7日期间仅有2%的患者有显著提升（熵下降>0.25），另有12%的患者因死亡而增加了确定性；在7日至14日期间，有14%的患者预后确定性显著提升，另有18%的患者因死亡而增加确定性。于第1天存活的患者中，初始预后为“不确定”的有2%，为“较差”的有10%的患者在第7天转入了更有利的预后类别；在第7天仍存活且仍在ICU的患者中，“不确定”预后的有31%，而“较差”预后的有16%在第14天转向更有利的类别。外部验证队列的结果相当一致。
> 
> 结论：对于入住ICU的血液系统恶性肿瘤患者，除因早期死亡导致预后确定性增加外，其长期生存预后的确定性在入ICU的前两周提升极为有限。尽管使用了丰富的ICU数据集和多种先进建模方法，模型总体性能仍较一般，提示该人群的预后主要受疾病特异性及个体相关因素影响，而不仅仅由ICU治疗过程决定。

### 第二部分 AI 大师评价

本研究旨在量化血液系统恶性肿瘤患者入住ICU后两周内长期生存预测确定性的变化。采用回顾性队列设计，利用不同时间节点的数据建立并验证一年生存率预测模型。结果显示，即使应用复杂建模策略和高质量数据集，前两周的预后确定性提升有限，主要变化来自早期死亡事件。该研究创新性地量化了“预后确定性”的动态演变，对时间限定试验设计具有启发意义，但样本量及模型表现限制了其应用推广。

---

## 9. 新型ECCO₂R技术在轻中度ARDS患者中的前瞻性临床评估：基于PRISMALUNG的超肺保护通气研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41495763)
**期刊：** Critical care (London, England)
**PMID：** 41495763
**DOI：** 10.1186/s13054-025-05827-4

### 第一部分 原文与翻译

**英文原标题：** A prospective clinical evaluation of new ECCO2R technology in mild to moderate ARDS patients: assessing ultra-lung-protective ventilation with PRISMALUNG.

> **英文摘要：**
> BACKGROUND: Extracorporeal carbon dioxide removal (ECCOR), when used as an adjunct to mechanical ventilation in patients with mild to moderate acute respiratory distress syndrome (ARDS), has been proposed as a strategy to control hypercapnic acidosis during ultra-lung-protective ventilation (ULPV). However, no multicenter study has systematically assessed ventilation improvement markers with a standardized protocol using ECCO₂R devices featuring a peristaltic pump design. This prospective, multicenter study conducted in France addresses these gaps by evaluating the performance and safety of PRISMALUNG+, a novel membrane lung specifically developed for ECCOR, either as a standalone therapy or combined with continuous renal replacement therapy (CRRT). A specific protocol for ULPV was used to minimize lung stress and mitigate the risk of hypoxemia.
> 
> METHODS: Between April 2021 and December 2023, 58 patients were treated with ECCOR (16 in combination with CRRT). Tidal volume (V) was reduced stepwise from 6 mL/kg to 4 mL/kg. Once the partial pressure of carbon dioxide (PaCO) exceeded 50 mmHg, sweep gas (100% oxygen at 10 L/min) was initiated to provide ECCOR. Outcomes were measured at 8 and 24 h, while safety was monitored until discharge or day 28.
> 
> RESULTS: During V reduction and before ECCOR initiation, peak hypercapnia and respiratory acidosis reached PaCO of 53.0 [50.0-55.0] mmHg and pH of 7.30 [7.24-7.36]. After 24 h of treatment, V significantly decreased from 6.0 [6.0-6.1] to 4.0 [4.0-4.30] (p < 0.0001), driving pressure (∆P) from 12.0 [10.0-16.0] cmHO to 10.0 [8.0-13.0] cmHO (p < 0.0001), ventilatory ratio (VR) from 1.7 [1.5-2.1] to 1.3 [1.0-1.6] (p < 0.0001) and mechanical power from 18.8 [15.0-22.0] J/min to 11.8 [8.8-15.5] J/min (p < 0.0001). PaO/FiO did not significantly change over time and respiratory acidosis resolved with treatment, as evidenced by normalization of pH and a reduction in PaCO. Importantly, no major bleeding events, intracranial hemorrhages, or hemolysis were reported during the study.
> 
> CONCLUSION: This study demonstrates that hypercapnic acidosis occurring during ultra-low V ventilation (ULPV) can be safely mitigated with ECCO₂R in mechanically ventilated patients with mild to moderate ARDS. Moreover, under ULPV, ∆P, VR and mechanical power were improved without inducing hypoxemia.
> 
> TRIAL REGISTRATION: Clinicaltrials.gov: NCT04617093, Registration date: 30 October 2020.

> **中文摘要：**
> 背景：在轻至中度急性呼吸窘迫综合征（ARDS）患者中，将体外二氧化碳清除（ECCO₂R）作为机械通气的辅助手段，已被提出用于在超肺保护通气（ULPV）过程中控制高碳酸血症性酸中毒的策略。然而，目前尚无多中心研究使用带有蠕动泵设计的ECCO₂R装置，通过标准化方案系统评估通气改善指标。本项于法国开展的前瞻性多中心研究针对这一空白，对新型专为ECCO₂R开发的膜肺PRISMALUNG+的性能与安全性进行了评估，该装置可单独使用或与连续性肾脏替代治疗（CRRT）联合应用。研究采用了特定的ULPV方案，以最大限度减少肺应激并降低低氧血症风险。
> 
> 方法：2021年4月至2023年12月，共有58例患者接受ECCO₂R治疗（其中16例联合CRRT）。潮气量（V）由6 mL/kg逐步降至4 mL/kg。当动脉二氧化碳分压（PaCO₂）超过50 mmHg时，启动扫气（100%氧气，10 L/min）以提供ECCO₂R。结果在治疗8小时和24小时测定，安全性则监测至出院或第28天。
> 
> 结果：在降低潮气量及启动ECCO₂R之前，峰值高碳酸血症和呼吸性酸中毒分别表现为PaCO₂ 53.0 [50.0–55.0] mmHg和pH 7.30 [7.24–7.36]。经过24小时治疗后，潮气量显著下降由6.0 [6.0–6.1] 至 4.0 [4.0–4.3]（p < 0.0001），驱动压（∆P）由12.0 [10.0–16.0] cmH₂O降至10.0 [8.0–13.0] cmH₂O（p < 0.0001），通气比（VR）由1.7 [1.5–2.1] 降至 1.3 [1.0–1.6]（p < 0.0001），机械功率由18.8 [15.0–22.0] J/min降至11.8 [8.8–15.5] J/min（p < 0.0001）。PaO₂/FiO₂随时间未显著变化，呼吸性酸中毒在治疗后得到纠正，表现为pH恢复正常及PaCO₂下降。值得注意的是，研究期间未报告重大出血事件、颅内出血或溶血。
> 
> 结论：本研究表明，在轻至中度ARDS机械通气患者中，于超低潮气量通气（ULPV）期间，可通过ECCO₂R安全地缓解高碳酸血症性酸中毒。此外，在ULPV条件下，∆P、VR及机械功率均显著改善而不引发低氧血症。
> 
> 试验注册：Clinicaltrials.gov：NCT04617093，注册日期：2020年10月30日。

### 第二部分 AI 大师评价

该研究通过多中心前瞻性设计，评估了新型PRISMALUNG+ ECCO₂R装置在轻中度ARDS患者中的性能与安全性。结果显示，其可在超低潮气量通气条件下有效纠正高碳酸血症性酸中毒，并显著改善驱动压、通气比及机械功率，而不增加低氧血症风险。研究突出设备在临床整合中的可行性，为AR​​DS的肺保护策略提供了新证据。其局限在于样本量相对有限且随访时间短，仍需进一步验证长期临床获益。

---

## 10. 将血氧饱和度/吸入氧浓度比值转换为动脉血氧分压/吸入氧浓度比值以评估重症患者呼吸衰竭的策略：系统综述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41493393)
**期刊：** Critical care medicine
**PMID：** 41493393
**DOI：** 10.1097/CCM.0000000000007018

### 第一部分 原文与翻译

**英文原标题：** Approaches to Converting Spo2/Fio2 Ratio to Pao2/Fio2 Ratio for Assessment of Respiratory Failure in Critically Ill Patients: A Systematic Review.

> **英文摘要：**
> OBJECTIVE: The Pao2/Fio2 (PF) ratio is widely used as an assessment of respiratory failure in guiding ventilation strategies and prognostication in critically ill patients. However, given that it mandates invasive arterial access, the Spo2/Fio2 (SF) ratio has been suggested as a noninvasive and readily accessible alternative. What are the best ways to convert SF and PF ratios in critically ill patients, in terms of their diagnostic/prognostic accuracy and clinical utility?
> 
> DATA SOURCES: We comprehensively searched databases (MEDLINE, Embase, Web of Science, Cochrane library) to identify relevant studies.
> 
> STUDY SELECTION: Any observational studies that compared the SF to PF ratio in critically ill patients. We assessed individual study risk of bias (ROB) using the revised QUADAS II tool.
> 
> DATA EXTRACTION: We included 45 observational studies, ranging from 61 to 141,000 measurements.
> 
> DATA SYNTHESIS: SF to PF imputation was less accurate when the Spo2 was equal to or greater than 97%. Otherwise, all studies were able to establish strong correlational relationships between SF and PF ratios, but there was no clear best equation. Based on ease of use, size, generalizability and methodology, we were able to prioritize four equations (one linear, one logarithmic linear, and two nonlinear). All four equations showed strong correlation between SF and PF ratios, with the linear equation being easiest to apply. The SF ratio also correlated well with clinical outcomes when compared with the PF ratio, both as an individual value and as part of a comprehensive score, with more discriminating performance in some cases.
> 
> CONCLUSIONS: SF and PF ratios demonstrate good correlation, and may have similar prognostic value. Although there is no clear optimal method to convert SF to PF ratios, linear equations show acceptable correlation and are most easily applied at the bedside.

> **中文摘要：**
> 目的：动脉血氧分压/吸入氧浓度（PF）比值被广泛用于评估重症患者的呼吸衰竭，以指导通气策略并进行预后评估。然而，由于PF比值需要进行侵入性动脉取样，血氧饱和度/吸入氧浓度（SF）比值被提出作为一种无创且易于获得的替代方法。本研究旨在探讨在重症患者中，将SF比值转换为PF比值的最佳方法，从诊断、预后准确性及临床实用性角度进行评估。
> 
> 数据来源：我们全面检索了MEDLINE、Embase、Web of Science及Cochrane图书馆等数据库，以识别相关研究。
> 
> 研究选择：纳入任何比较重症患者SF与PF比值关系的观察性研究。使用修订版QUADAS II工具评估每项研究的偏倚风险。
> 
> 数据提取：共纳入45项观察性研究，测量样本数范围从61例至141,000例。
> 
> 数据综合：当血氧饱和度（Spo2）≥97%时，SF到PF的推算结果准确性较低。除此之外，所有研究均建立了SF与PF比值之间的强相关关系，但尚无明确的最佳转换方程。综合考虑易用性、样本量、普适性及方法学质量，我们优先推荐了四个方程（一个线性、一个对数线性及两个非线性方程）。这四个方程均显示SF与PF比值之间具有高度相关性，其中线性方程最易于临床应用。SF比值与PF比值相比，无论作为单值指标还是综合评分的一部分，也都与临床结局具有良好的相关性，且在部分研究中具有更强的区分能力。
> 
> 结论：SF与PF比值具有良好的相关性，并可能具有相似的预后价值。尽管尚无明确的最佳SF转PF转换方法，但线性方程显示出可接受的相关性，且最适合于临床床旁应用。

### 第二部分 AI 大师评价

本系统综述旨在系统评估不同算法将SF比值转换为PF比值在重症患者呼吸衰竭评估中的可行性及准确性。研究纳入45项观察性研究，结果显示除高Spo2（≥97%）时外，SF与PF比值均具有强相关性，但尚无统一最优转换方程。作者综合了多种模型，推荐线性方程在临床应用中最实用。本研究通过整合大样本数据，为SF替代PF提供了理论支持，但其局限在于转换准确度受高血氧饱和度影响，且缺乏统一标准方程。

---

## 11. 呼吸道合胞病毒介导的 Gas6/Axl 轴通过诱导低反应性巨噬细胞促进鼻咽部肺炎链球菌增殖

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41493058)
**期刊：** The Journal of infectious diseases
**PMID：** 41493058
**DOI：** 10.1093/infdis/jiag004

### 第一部分 原文与翻译

**英文原标题：** Respiratory syncytial virus-mediated Gas6/Axl axis induces hyporesponsive macrophages to promote pneumococcal proliferation in the nasopharynx.

> **英文摘要：**
> BACKGROUND: Streptococcus pneumoniae commonly colonizes the nasopharynx of children asymptomatically, but under certain conditions, it can cause invasive diseases such as pneumonia. The mechanisms driving this transition are not fully understood.
> 
> METHODS: In this study, we utilized a pneumococcal nasopharyngeal colonization model and subsequent respiratory syncytial virus (RSV) infection to investigate the mechanism of bacterial expansion. We observed loads in nasal and bronchoalveolar lavage fluids. We also measured the expression of the growth arrest-specific protein 6 (Gas6) in the nasal lavage. We further assessed the effect of selective inhibition of the Axl receptor using BGB324 on RSV-mediated growth. Macrophage phenotypes were analyzed in vivo using M1-like markers and confirmed in vitro using Gas6-treated bone marrow-derived macrophages.
> 
> RESULTS: We observed increased loads in nasal and bronchoalveolar lavage fluids following RSV infection. RSV infection also upregulated the expression of Gas6 in the nasal lavage, and selective inhibition of the Axl receptor using BGB324 effectively attenuated RSV-mediated growth. In addition, compared with mice with colonization alone, mice with subsequent RSV infection exhibited decreased expression of M1-like macrophage markers in the nasal cavity. In vitro assays confirmed that Gas6 suppressed M1 macrophage polarization, fostering an immunosuppressive microenvironment conducive to bacterial proliferation.
> 
> CONCLUSIONS: Our findings reveal that the RSV infection-induced Gas6/Axl axis facilitates pneumococcal overgrowth by modulating macrophage function. Targeting the RSV-induced Gas6/Axl axis or modulating macrophage polarization may offer novel therapeutic strategies for preventing or managing severe pneumococcal infections exacerbated by viral pathogens such as RSV.

> **中文摘要：**
> 背景：肺炎链球菌常在儿童的鼻咽部无症状定植，但在特定条件下可引起诸如肺炎等侵袭性疾病。驱动这一转变的机制尚不完全清楚。
> 
> 方法：本研究采用肺炎链球菌鼻咽定植模型及后续呼吸道合胞病毒（RSV）感染，探讨细菌扩增的机制。我们检测了鼻腔冲洗液和支气管肺泡灌洗液中的细菌负荷，并测定了鼻腔冲洗液中生长停滞特异性蛋白6（Gas6）的表达。此外，使用 BGB324 选择性抑制 Axl 受体，以评估其对 RSV 介导生长的影响。巨噬细胞表型通过体内 M1 型标志物分析，并在体外以 Gas6 处理的骨髓来源巨噬细胞加以验证。
> 
> 结果：RSV 感染后，鼻腔冲洗液和支气管肺泡灌洗液中的细菌负荷显著增加。RSV 感染还上调了鼻腔冲洗液中 Gas6 的表达，而使用 BGB324 选择性抑制 Axl 受体可有效减弱 RSV 介导的细菌增殖。此外，与仅有定植的小鼠相比，随后感染 RSV 的小鼠在鼻腔中的 M1 型巨噬细胞标志物表达下调。体外实验进一步证实，Gas6 可抑制 M1 型巨噬细胞极化，从而形成有利于细菌增殖的免疫抑制性微环境。
> 
> 结论：本研究结果揭示，RSV 感染诱导的 Gas6/Axl 轴通过调节巨噬细胞功能促进肺炎链球菌过度生长。靶向 RSV 诱导的 Gas6/Axl 轴或调节巨噬细胞极化，可能为预防或治疗病毒病原体（如 RSV）加重的严重肺炎链球菌感染提供新的治疗策略。

### 第二部分 AI 大师评价

该研究旨在揭示呼吸道合胞病毒（RSV）感染如何通过调控宿主免疫微环境促进肺炎链球菌的扩增。研究者结合体内外实验，发现 RSV 可诱导鼻腔中 Gas6/Axl 轴的激活，从而抑制巨噬细胞的 M1 型极化，形成有利于细菌生长的免疫抑制环境。阻断 Axl 受体能有效减少 RSV 相关的细菌过度生长。研究在机制层面深化了对病毒-细菌共感染相互作用的理解，其创新性在于明确了 Gas6/Axl 信号在宿主免疫调控中的关键作用，但仍需在临床模型中进一步验证其潜在治疗价值。

---

## 12. Levosimendan 促进重度心源性休克患者从体外膜氧合（ECMO）撤机的作用：LEVOECMO 随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41324946)
**期刊：** JAMA
**PMID：** 41324946
**DOI：** 10.1001/jama.2025.19843

### 第一部分 原文与翻译

**英文原标题：** Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Levosimendan may facilitate weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) and improve survival, but supporting evidence remains limited.
> 
> OBJECTIVE: To assess whether early administration of levosimendan reduces the time to successful VA-ECMO weaning in patients with severe but potentially reversible cardiogenic shock.
> 
> DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted across 11 intensive care units (ICUs) in France. Between August 27, 2021, and September 10, 2024, 205 adult patients with acute cardiogenic shock who had started VA-ECMO in the preceding 48 hours were enrolled. Final follow-up was completed on November 10, 2024.
> 
> INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive levosimendan, 0.15 μg/kg per minute, to be increased to 0.20 μg/kg per minute after 2 hours (n = 101), or placebo (n = 104).
> 
> MAIN OUTCOMES AND MEASURES: The primary outcome was time to successful ECMO weaning within 30 days following randomization. Secondary outcomes included ECMO-, mechanical ventilation-, and organ failure-free days, ICU and hospital lengths of stay, serious adverse events, and all-cause 30- and 60-day mortality.
> 
> RESULTS: Among the 205 randomized patients (median age, 58 [IQR, 50-67] years; 149 [72.7%] male), main cardiogenic shock etiologies were postcardiotomy (79 [38.5%]), acute myocardial infarction (56 [27.3%]), and myocarditis (28 [13.7%]). Treatment dose was increased to 0.20 ± 0.01 μg/kg per minute in 93% of patients receiving levosimendan and in 96% of those receiving placebo. Within 30 days, 69 of 101 patients (68.3%) had a successful ECMO weaning in the levosimendan group compared with 71 of 104 (68.3%) in the placebo group (risk difference, 0.0% [95% CI, -12.8% to 12.7%]; subdistribution hazard ratio, 1.02 [95% CI, 0.74-1.39]; P = .92). In the levosimendan and placebo groups, respectively, median ECMO duration (5 [IQR, 4-7] days vs 6 [IQR, 4-11] days; P = .53), mean ICU length of stay (18 [SD, 15] days vs 19 [SD, 15] days; P = .42), and 60-day mortality (27.7% vs 25.0%; risk difference, 2.7% [95% CI, -9.0% to 15.3%]; P = .78) did not differ significantly. Ventricular arrhythmias occurred more frequently with levosimendan (18 [17.8%] vs 9 [8.7%]; absolute risk difference, 9.2% [95% CI, 0.4%-18.1%]).
> 
> CONCLUSIONS AND RELEVANCE: Among patients with severe but potentially reversible cardiogenic shock supported by VA-ECMO, early levosimendan administration did not significantly reduce the time to successful weaning of ECMO compared with placebo.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04728932.

> **中文摘要：**
> 重要性：Levosimendan 可能有助于从静脉-动脉体外膜氧合（VA-ECMO）撤机并改善生存率，但支持性证据仍有限。
> 
> 研究目的：评估早期使用 levosimendan 是否可缩短重度但具有潜在可逆性的心源性休克患者成功撤离 VA-ECMO 的时间。
> 
> 研究设计、场所与参与者：这是一项在法国 11 家重症监护病房（ICU）开展的随机、双盲、安慰剂对照试验。2021 年 8 月 27 日至 2024 年 9 月 10 日期间，纳入了 205 名在前 48 小时内启动 VA-ECMO 的急性心源性休克成人患者。最终随访于 2024 年 11 月 10 日完成。
> 
> 干预措施：患者按 1:1 比例随机分配接受 levosimendan（0.15 μg/kg 每分钟，2 小时后可增至 0.20 μg/kg 每分钟，n=101），或安慰剂（n=104）。
> 
> 主要结局与测量指标：主要结局为随机化后 30 天内成功撤离 ECMO 的时间。次要结局包括撤机后无 ECMO、机械通气及器官功能衰竭的天数，ICU 及住院时间，严重不良事件，以及 30 日和 60 日全因死亡率。
> 
> 结果：在 205 名随机患者中（中位年龄 58 岁 [四分位距 50-67 岁]；男性 149 名 [72.7%]），主要心源性休克病因为心脏手术后（79 例，38.5%）、急性心肌梗死（56 例，27.3%）及心肌炎（28 例，13.7%）。治疗剂量分别在 levosimendan 组 93% 和安慰剂组 96% 的患者中增至 0.20 ± 0.01 μg/kg 每分钟。30 天内，levosimendan 组 69/101 例（68.3%）和安慰剂组 71/104 例（68.3%）实现 ECMO 成功撤机（风险差 0.0%，95% CI：-12.8%-12.7%；亚分布风险比 1.02，95% CI：0.74-1.39；P=.92）。两组在 ECMO 中位持续时间（5 [四分位距 4-7] 天 vs 6 [四分位距 4-11] 天；P=.53）、平均 ICU 住院时长（18 [SD 15] 天 vs 19 [SD 15] 天；P=.42）及 60 日死亡率（27.7% vs 25.0%；风险差 2.7%，95% CI：-9.0%-15.3%；P=.78）方面无显著差异。Levosimendan 组心室性心律失常发生更频繁（18 例 [17.8%] vs 9 例 [8.7%]；绝对风险差 9.2%，95% CI：0.4%-18.1%）。
> 
> 结论与意义：在接受 VA-ECMO 支持的重度但有潜在可逆性的心源性休克患者中，早期使用 levosimendan 并未显著缩短成功撤除 ECMO 的时间，相较于安慰剂无明显优势。
> 
> 试验注册：ClinicalTrials.gov 标识码 NCT04728932。

### 第二部分 AI 大师评价

本研究为法国多中心、随机、双盲、安慰剂对照的临床试验，评估 levosimendan 能否促进重症心源性休克患者从 VA-ECMO 中成功撤机。结果显示，该药物并未缩短撤机时间或改善生存率，与安慰剂相比差异不显著，但伴有更高的心律失常风险。研究设计严谨，样本量充足，结论对 ECMO 管理有实际指导意义。然而，结果提示 levosimendan 在此类患者中临床效益有限，值得进一步机制与亚组探索。

---

## 13. 维生素C通过趋化作用和抗炎机制增强小鼠角膜真菌感染的治疗效果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41312993)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41312993
**DOI：** 10.1128/aac.01165-25

### 第一部分 原文与翻译

**英文原标题：** Vitamin C enhances corneal fungal infection treatment in mice via chemotaxis and anti-inflammation.

> **英文摘要：**
> Fungal keratitis (FK) is a persistent and vision-threatening disease. The potential of vitamin C (VC) in tissue protection is well-recognized; however, its specific role in FK and its interaction with antifungal drugs are not well defined. In this study, we investigated the role of VC in FK  and . It revealed that VC substantially decreases clinical scores and corneal perforation rates in a murine model of FK. VC promoted a concentration-dependent increase in neutrophil infiltration via mast cells  and confirmed this effect in  experiments. Moreover, VC enhanced fungicidal activity by boosting infiltrated neutrophils, without influencing reactive oxygen species (ROS) production or neutrophil extracellular traps (NETs) formation. VC also mitigated the cytokine storm within bone marrow-derived macrophages and increased neutrophil apoptosis, thereby facilitating the efficient clearance of senescent neutrophils. The combination of VC with amphotericin B (AmB) demonstrated additive antifungal effects, reducing fungal load and corneal perforation. These results indicate that VC is pivotal in defending against fungal corneal infections by promoting neutrophil chemotaxis through mast cells (MCs) and modulating the inflammatory response, without suppressing neutrophils' antifungal capability. The combination of VC with AmB may present a new therapeutic avenue for FK.

> **中文摘要：**
> 真菌性角膜炎（FK）是一种持续性且具有致盲危险的疾病。维生素C（VC）在组织保护方面的潜力广为认可；然而，其在FK中的具体作用及其与抗真菌药物的相互作用尚未明确。本研究探讨了VC在FK中的作用。结果显示，在小鼠角膜真菌感染模型中，VC显著降低了临床评分和角膜穿孔率。VC通过肥大细胞介导的方式，以浓度依赖性促进中性粒细胞的浸润，并在体外实验中验证了这一效应。此外，VC通过增强浸润中性粒细胞的杀真菌活性而提高抗真菌效能，而不影响活性氧（ROS）的生成或中性粒细胞胞外捕获网（NETs）的形成。VC还减轻了骨髓来源巨噬细胞的细胞因子风暴，并促进中性粒细胞凋亡，从而有助于老化中性粒细胞的高效清除。VC与两性霉素B（AmB）联合使用时显示出叠加的抗真菌效果，可降低真菌负荷并减少角膜穿孔。这些结果表明，VC通过肥大细胞促进中性粒细胞趋化并调节炎症反应，在防御角膜真菌感染中发挥关键作用，同时不抑制中性粒细胞的抗真菌能力。VC与AmB的联合可能为FK治疗提供新的治疗途径。

### 第二部分 AI 大师评价

本研究旨在阐明维生素C在真菌性角膜炎治疗中的具体机制与协同作用。作者通过小鼠模型和体外实验发现，维生素C不仅能通过肥大细胞促进中性粒细胞的趋化，还能增强其杀真菌活性，同时调节炎症反应并降低角膜破坏。与两性霉素B联合使用时，产生叠加的抗真菌效果。该研究创新性地揭示了维生素C在角膜免疫防御中的调节作用，为FK治疗提供了新思路，但仍需进一步验证其临床应用安全性与剂量依赖关系。

---

## 14. 重度感染早产与足月新生儿中哌拉西林-他唑巴坦的人群药代动力学与剂量优化研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41288085)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41288085
**DOI：** 10.1128/aac.00998-25

### 第一部分 原文与翻译

**英文原标题：** Population pharmacokinetics and dose optimization of piperacillin-tazobactam in premature and term neonates with severe infections.

> **英文摘要：**
> Piperacillin-tazobactam is widely used off-label in neonates for the empirical treatment of severe infections, resulting in diverse dosing regimens across clinical settings. This variability, combined with high interindividual differences in renal maturation that impact drug disposition, complicates standardized dosing and emphasizes the need for individualized, evidence-based strategies. This study aimed to develop and evaluate a population pharmacokinetic model of piperacillin in neonates to support optimized initial dosing recommendations. Neonatal patients (postnatal age ≤28 days) admitted to an intensive care unit who received piperacillin-tazobactam (8:1 ratio) at Neofax-recommended doses were included. Plasma concentrations were measured using an ultra-high-performance liquid chromatography with tandem mass spectrometry method. Population pharmacokinetic analysis for piperacillin was performed using nonlinear mixed-effects modeling. A total of 65 blood samples were collected from 25 neonates, both preterm (56%) and full-term. Piperacillin pharmacokinetics was best described by a one-compartment model incorporating body weight-based allometric scaling, postmenstrual age, and serum creatinine as covariates influencing clearance. For a typical neonate in the study (1.76 kg), the estimated clearance was 0.748 L/h (coefficient of variation, 38.3%), and the volume of distribution was 0.866 L (37.7%). Simulations indicated adequate probability of target attainment with current recommendations, but a high proportion of preterm neonates (>75%) were at risk of overexposure (trough piperacillin plasma concentration >50 mg/L). Additional simulations supported individualized initial regimens based on renal maturation and suggested that extended infusions (1-4 h) may improve target attainment for stricter targets and less-susceptible pathogens. This study provides a validated pharmacokinetic model for piperacillin in neonates with severe infections, offering a framework to optimize empiric dosing based on renal function and developmental stage.

> **中文摘要：**
> 哌拉西林-他唑巴坦广泛用于新生儿重度感染的经验性治疗（非适应证使用），导致不同临床环境中出现多样化的给药方案。这种差异性，加之肾脏发育成熟度存在较大个体差异，对药物处置具有显著影响，使标准化给药变得复杂，并凸显了基于证据的个体化治疗策略的必要性。本研究旨在建立和评估新生儿哌拉西林的人群药代动力学模型，以支持优化初始给药建议。纳入对象为入住重症监护室并接受 Neofax 推荐剂量哌拉西林-他唑巴坦（8:1 比例）的新生儿（出生后年龄≤28天）。采用超高效液相色谱-串联质谱法测定血浆药物浓度。利用非线性混合效应模型进行哌拉西林的人群药代动力学分析。共从25例新生儿（其中早产儿占56%，足月儿占44%）收集65份血样。哌拉西林的药代动力学最符合单室模型，其清除率受体重基于的异速生长、胎龄后周数及血清肌酐影响。对于研究中的典型新生儿（体重1.76 kg），估算的清除率为0.748 L/h（变异系数38.3%），分布容积为0.866 L（37.7%）。模拟结果显示，目前推荐剂量能够达到足够的药效目标达标概率，但有较大比例的早产儿（>75%）存在药物暴露过高风险（哌拉西林谷浓度>50 mg/L）。进一步的模拟支持基于肾脏发育程度制定个体化初始给药方案，并提示延长输注时间（1–4小时）可能改善对更严格目标及耐药性更强病原体的达标率。本研究提供了一个针对新生儿重度感染的哌拉西林验证性药代动力学模型，为基于肾功能和发育阶段的经验性给药优化提供了理论框架。

### 第二部分 AI 大师评价

该研究针对新生儿群体，尤其是早产儿，构建并验证了哌拉西林的人群药代动力学模型，旨在为哌拉西林-他唑巴坦的初始剂量优化提供量化依据。研究通过非线性混合效应模型分析，确定了体重、胎龄后周数及血清肌酐对清除率的主要影响因素。模拟结果揭示当前标准剂量可能导致部分早产儿药物过度暴露，并建议基于肾脏成熟度进行个体化初始给药及延长输注疗法以改善目标达成率。该研究创新性在于提供了新生儿人群的药代动力学参考模型，但仍受样本量有限及单中心设计的局限。

---

## 15. 发热性中性粒细胞减少症血液病患者中哌拉西林-他唑巴坦的群体药代动力学及优化给药方案研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41288084)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41288084
**DOI：** 10.1128/aac.01253-25

### 第一部分 原文与翻译

**英文原标题：** Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia.

> **英文摘要：**
> Hematological patients with febrile neutropenia receiving piperacillin-tazobactam may experience pharmacokinetic alterations that compromise drug exposure. We aimed to characterize the population pharmacokinetics of piperacillin in plasma and provide optimized dosing recommendations for this patient population. A population pharmacokinetic analysis was conducted in patients who received piperacillin-tazobactam as part of the BEATLE study, which compared the efficacy, safety, and pharmacokinetic/pharmacodynamic target attainment of β-lactams administered in extended infusion versus short 30 min infusion in adult hematological patients with febrile neutropenia. Monte Carlo simulations were performed to evaluate, for each dosing regimen, the probability of attaining (i) an efficacy target of unbound piperacillin concentrations above the minimum inhibitory concentration (MIC) of the bacteria for the entire dosing interval (100% ƒ), and (ii) a toxicity threshold of ≥160 mg/L. A total of 44 patients and 221 plasma concentrations were included. A one-compartment model best described piperacillin plasma pharmacokinetics, with Cockcroft-Gault creatinine clearance (CrCL) significantly influencing drug clearance. Dosing simulations showed that extended and continuous infusions were superior to short 30 min infusions in the attainment of 100% ƒ, even for bacteria with low to intermediate MIC (≤2-4 mg/L). In patients with higher CrCL (>90 mL/min) or infections caused by less susceptible Gram-negative bacilli (MIC: 8-16 mg/L), only continuous infusions of 12-16 g/day were likely to achieve 100% ƒ. These findings support the use of extended or continuous infusions of piperacillin in the initial management of patients with febrile neutropenia, particularly in patients with higher CrCL or when infections caused by less susceptible pathogens, such as , are suspected.

> **中文摘要：**
> 接受哌拉西林-他唑巴坦治疗的发热性中性粒细胞减少症血液病患者可能出现药代动力学改变，从而影响药物暴露。本研究旨在描述该人群中哌拉西林在血浆中的群体药代动力学特征，并为该类患者提供优化的给药建议。研究在参与 BEATLE 研究的患者中进行，该研究比较了在发热性中性粒细胞减少症成人血液病患者中，以延长输注与短时（30 分钟）输注方式给予β-内酰胺类药物在疗效、安全性及药代/药效学靶达成率方面的差异。采用蒙特卡洛模拟评估不同给药方案下达到以下两项目标的概率：（i）游离哌拉西林浓度在整个给药间期维持高于最小抑菌浓度（MIC）的疗效目标（100%ƒ）；（ii）血药浓度达到≥160 mg/L 的毒性阈值。共纳入44例患者及221个血浆浓度数据。单室模型最能描述哌拉西林的血浆药代动力学特征，其中 Cockcroft-Gault 公式计算的肌酐清除率（CrCL）对药物清除具有显著影响。剂量模拟结果显示，与30分钟短时输注相比，延长或持续输注在实现100%ƒ目标方面更具优势，即使对低至中等 MIC（≤2–4 mg/L）的细菌亦然。对于 CrCL 较高（>90 mL/min）的患者或感染由低敏感的革兰阴性杆菌（MIC：8–16 mg/L）引起时，仅每日持续输注 12–16 g 才有可能达到100%ƒ目标。这些发现支持在发热性中性粒细胞减少症患者的初始治疗中采用延长或持续输注的哌拉西林方案，尤其适用于 CrCL 较高或疑似感染低敏感病原体的情况。

### 第二部分 AI 大师评价

该研究通过群体药代动力学分析，系统评估了哌拉西林-他唑巴坦在发热性中性粒细胞减少症血液病患者中的药物暴露特征。使用蒙特卡洛模拟量化不同输注方案在疗效与安全性阈值下的目标达成概率。结果证明延长和持续输注方式在药效维持方面优于短时输注，特别是在高肾功能或感染耐药病原体的患者中。该研究为抗菌药个体化给药提供了重要依据，但样本量有限及特定病原体类型未充分分析仍是其局限所在。

---

速递结束，祝您工作愉快！